Cynata Therapeutics Limited (CYYNF)
OTHER OTC:CYYNF
CYYNF Stock Chart & Stats
$0.15
-$0.05(-27.37%)
At close: 4:00 PM EST
$0.15
-$0.05(-27.37%)
Day’s Range― - ―
52-Week Range$0.08 - $0.22
Previous CloseN/A
Volume3.30K
Average Volume (3M)66.00
Market Cap
$49.46M
Enterprise Value$71.02M
Total Cash (Recent Filing)$5.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding237,454,380
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market Cap1.44
Enterprise Value/Revenue37.67
Enterprise Value/Gross Profit37.67
Enterprise Value/Ebitda-7.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$4.50M
Bulls Say, Bears Say
Bulls Say
Proprietary Cymerus MSC PlatformThe Cymerus iPSC-derived MSC platform is a durable technical moat: it enables scalable, off-the-shelf allogeneic cell production and reduces donor variability. That platform breadth supports multiple indications and makes partnering or licensing commercially attractive over the medium term.
Debt-free Balance SheetZero debt materially lowers financial distress risk and preserves strategic flexibility for a clinical-stage biotech. With no leverage, management can prioritize R&D or negotiate partnerships without immediate debt service constraints, a lasting strength amid ongoing cash burn.
High Gross Margins With Revenue RecoveryNear-100% gross margins reflect the software-like economics of licensing/therapy royalties and low incremental COGS for cell therapies once manufactured at scale. Combined with modest revenue recovery, this suggests durable upside if development programs or partnerships convert to recurring revenue.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow indicates ongoing cash burn that will require external funding to sustain trials and commercialization. Reliance on capital raises or partners can be dilutive or constrain strategy, reducing long-term financial independence and execution certainty.
Large Recurring Operating LossesConsistently large operating losses highlight structural unprofitability until product approval or substantial partner deals occur. High fixed R&D and SG&A relative to current revenue mean margins will remain under pressure absent material clinical or commercial milestones.
Erosion Of Equity And Asset BaseMaterial decline in shareholders' equity and assets over recent years reflects cumulative losses and reduces the capital buffer against setbacks. This degradation limits balance-sheet capacity to self-fund late-stage development and weakens negotiating leverage with partners or licensors.
Cynata Therapeutics Limited News
CYYNF FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest stock price was $0.08 and its highest was $0.22 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is $49.46M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 157 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.008.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 237,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in CYYNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CYYNF Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
-179.37%
Trailing 12-Months
Asset Growth
-62.21%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
AnteoTech Ltd
―
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―